Related Experiment Video

Updated: Aug 5, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

Targeting CRMP2 for Chronic Pain: From Molecular Mechanisms to Therapeutic Strategies

Jia-Yi Wang1, Dai-Qiang Liu1, Ya-Qun Zhou1

  • 1Department of Anesthesiology and Pain Medicine, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Biomedicines
|July 28, 2026
PubMed

Insights

Collapsin Response Mediator Protein 2 (CRMP2) is key in chronic pain by altering cell functions. Targeting CRMP2 offers a promising, non-opioid approach for pain management, with new therapies showing potential.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Collapsin Response Mediator Protein 2 (CRMP2) is implicated in chronic pain pathogenesis.
  • CRMP2 acts as a molecular switch regulating microtubule dynamics, ion channel trafficking, and synaptic plasticity.
  • Aberrant post-translational modifications (PTMs) of CRMP2, like phosphorylation and SUMOylation, drive pain sensitization.

Purpose of the Study:

  • To systematically review CRMP2's structure, regulation, and role in pain signaling.
  • To critically evaluate CRMP2-targeted therapeutic strategies for chronic pain.
  • To explore the potential of CRMP2-based non-opioid analgesics.

Main Methods:

  • Literature review of CRMP2's function in pain pathways.
  • Analysis of preclinical data for CRMP2-targeted therapies.
  • Examination of challenges and innovations in CRMP2 drug development.

Main Results:

  • CRMP2 dysregulation is a critical driver of peripheral and central sensitization.
  • Various CRMP2-targeted strategies (small molecules, peptides, gene silencing) show preclinical efficacy.
  • CRMP2-based therapies offer potential as non-opioid analgesics.

Conclusions:

  • CRMP2 is a significant therapeutic target for chronic pain.
  • Innovations in delivery, precision medicine, and AI will advance CRMP2-based analgesics.
  • CRMP2-targeted therapies represent a paradigm shift in non-opioid pain management.
Keywords:
CRMP2chronic painneuroimmune interactionsynaptic plasticity

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Nociception01:44

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...